Evaluation of Antimicrobial Susceptibility Pattern of Pseudomonas Aeruginosa with Special Reference to MBL Production in a Tertiary Care Hospital

Dr. B.Anuradha[1], Uzma Afreen[2] and M. Praveena[3]

[1] Mamata Medical college

Received: 16 December 2013 Accepted: 1 January 2014 Published: 15 January 2014

Abstract

Background: Pseudomonas aeruginosa is emerging as a nosocomial pathogen by producing Metallo Beta lactamases and acquiring resistance to many antimicrobial agents.Materials and methods: 132 isolates of Pseudomonas aeruginosa from various clinical samples were tested for MBL production by double disk synergy method. Antibiotic susceptibility pattern was done by comparing non-MBL producers and MBL producers.Results: Pseudomonas aeruginosa was isolated from Pus-39.39

Index terms— bacterial infection, carbapenem resistance, carbapenemase, mbl producers, multi drug resistance, pseudomonas aeruginosa, routinely used antibiotics, n

1 Introduction

seudomonas aeruginosa is a Gram negative motile bacillus, belongs to the family Pseudomonaceae. It is found in moist environment, disinfectant solutions, water due to its ability to utilize many different organic compounds and survive in nutrient deficient conditions **??**Nadeem etal 2009). It is a leading cause of nosocomial infection especially critical ill and immune-compromised patients **??**Hugbo etal 1992). It has been implicated in diverse nosocomial pneumonia, urinary tract infection, surgical site infection, severe burns and infection of patients undergoing chemotherapy for neoplastic diseases or those on antibiotics therapy (Erdem 1999). It has intrinsic resistance to many antimicrobial agents and show resistance to many antibacterial agents. The mechanism of resistance is due to cell wall permeability, production of extracellular chromosomal and plasmid mediated ?lactamases (Livermore 1989), aminoglycoside modifying enzymes, cephalosporinases (Prince 1986), and active multidrug efflux mechanism (Li et al 1994). This multidrug resistant Pseudomonas aeruginosa causes nosocomial infections which is a global health care problem as it prolongs the duration of hospitalisation and increases the cost of the patient care.. The role of Carbapenems in the treatment of serious bacterial infections caused by ? -lactamase resistant bacteria is a great advancement. The Carbapenems available for use in India are Imipenem and Meropenem (Gupta et al 2006). However Carbapenem resistance has been observed frequently in Pseudomonas aeruginosa which is due to decreased outer membrane permeability, increase efflux system, alteration of penicillin binding protein and Carbepenem hydrolysing enzyme -carbepenamase (Gladstone et al 2005). They have potent hydrolyzing activity not only against carbepanamase but also against other ? lactamase antibiotics (Bush 1998 and **??**ennet 1999).

These MBL producing P. aeruginosa strains have been reported to be important cause of nosocomial infection associated with clonal spread **??**Bush etal 1995).

Therefore detection of MBL producing Gram negative bacilli especially Pseudomonas aeruginosa is crucial for the optimal treatment of patients particularly in critical ill and hospitalized patients to control the spread of resistance **??**Richet etal 2001). Studies about resistant organisms, their impact on health care and cost are important. Detection of emerging resistance to various antibiotics and proper guidelines for empirical therapy are important. Hence the present study is taken up to detect Metallo-beta-lactamase production in pseudomonas

aeruginosa in various clinical isolates and also to know the susceptibility pattern of MBL and non MBL producers to various antibiotics.

2 II.

3 Materials and Methods

A cross sectional study was conducted on 132 Pseudomonas aeruginosa strains isolated from different clinical specimens like pus, wound swabs, urine, sputum, body fluids, endotracheal tube secretions, and stool and ear swabs. The following parameters were noted such as age of patient, sex, type of clinical specimen, antibiotic usage and duration of hospital stay, history of Diabetes mellitus, pregnancy, malignancy and alcoholism, history of lung disorders, smoking, any immunosuppressant condition and history of urinary catheterization. The Pseudomonas aeruginosa isolates were confirmed by biochemical reactions as per the standard conventional methods. Standard strain of Pseudomonas aeruginosa ATCC 27853 was used as control.

Antibiotic Sensitivity was performed by Kirby -Bauer Disc Diffusion method and the results are recorded as per CLSI recommendation (David Greenwood etal 2008) The antibiotics used were Gentamicin(10ug), Azithromycin(50ug), Ciprofloxacin (5mcg), Cefepime(30ug), Ceftazidime(30ug), ceftriaxone (30mcg), Piperacillin,/Tazobactom(100/10ug), colistin (10ug), Aztreonam(10ug), Meropenem(10ug), Imipenem (10ug). Sensitivity pattern was determined by measuring the zones of inhibition with a calibrated ruler and comparing with the standard reference chart (supplied by Hi media Laboratories).

All Pseudomonas aeruginosa isolates were tested for MBL enzyme production by Double Disk Synergy Test (DDST) as per CLSI guidelines using 10 µg imipenem discs with EDTA-On a plate of Mueller Hinton agar two Imipenem discs (10mcg) were placed and 10mcl of 0.5M EDTA solution was added to one of the discs and incubated over night at 37 degrees. The zones of inhibition around Imipenem and Imipenem-EDTA discs were noted and compared. In case of MBL producers the zone of inhibition around Imipenem and EDTA disc was more than 7mm compared to Imipenem disc alone.

4 III.

5 Results

Out of 132 Clinical isolates of Pseudomonas aeruginosa 52 (39.39%) were isolated from pus, 50 (37.87%) were isolated from urine, 10 (7.57%) were isolated from sputum, 4 (3.03%) from endotracheal (ET) secretions, 2 (1.54%) from Pleural fluid, 4 (3.03%) from stool sample, 2(1.54%) from Ascitic fluid (ASF), and 6(4.54%) from Broncho alveolar lavage fluid (BAL). (Table : 1

6 Discussion

Out of 132 clinical isolates of Pseudomonas aeruginosa 52 (39.39%) were from pus samples followed by 50 (37.87%) urine samples. In one study by **??**ashir etal (Bashir etal 2011), among MBL producers 27.3% from urine, followed by 24.2% from wound infections. In 2008 Javiya et al **??**Javiya etal 2008) reported the highest number of Pseudomonas infection was found in urine followed by pus and sputum which indicates that wound infections and Urinary tract infections are the most common hospital acquired infections. These are the most important cause of morbidity in general population and also in hospitalized patients. In our study 90.5% of isolates were from inpatients and 9.5% were out patients, all MBL producers were from in-patients which show that Pseudomonas aeruginosa mainly causes nosocomial infections. Our study is correlating with Bashir etal 2011. Pseudomonas aeruginosa infections were seen almost equally in both males and females with 53.03% and 46.96% respectively. Among the isolates of Pseudomonas aeruginosa 24.24%cases were in the age group of 21 to 30 followed by 16.66% were in the age group of 31 to 40 only 4.54% were above 71 years. There was a slight variation with other studies in age but pseudomonas infections are distributed in all age groups.

MBL producing Pseudomonas aeruginosa is emerging as nosocomial pathogen and cause of concern for clinicians. It has the ability to acquire resistance to broad spectrum ? -lactam antimicrobial agents which include 3 rd generation Cephalosporins, Cephamycin, Carbepenems, Gentamicin and Fluoroquinolones. This MBL enzyme production has a potential to spread rapidly and to different Gram negative bacilli such as E.coli, Klebsiella and no suitable antimicrobial agents are available. In our study among the 132 isolates of Pseudomonas aeruginosa 44(33.34%) were MBL producers and 88 (66.66%) were non producers. Among the MBL producers majority were Pus samples 18 (40.90) followed by urine samples 16(36.36%) and 4 (9.09%) sputum. This indicates that MBL production among the isolates of Pseudomonas aeruginosa significant problem in wound infection followed by urinary tract infection. In our study prevalence of MBL producing Pseudomonas aeruginosa strains was 33% as the studies from other parts of India showing variable prevalence rate. In one study by Attal Ro in 2010 showed 11.4%, Navaneeth et al in 2000 12%, [They also observed that MBL producing Pseudomonas aeruginosa strains were 95% sensitive to Colistin. Our results are nearer to the above study. Our results are similar to Seema etal 2012 where both MBL and non MBL producers were 100% sensitive to colistin. , MBL producers were 0% sensitive and non MBL producers were 20% sensitive to Aztreonam. This shows that MBL producing Pseudomonas aeruginosa is developing resistance to routinely used antibiotics compared to non MBL

producers. A 'p' value <0.05 was considered to be significant. This emerging drug resistance in Pseudomonas aeruginosa is causing problems in treatment, increasing the mortality rates and prolonged hospitalization.

V.

7 Conclusion

Pseudomonas aeruginosa continues to be leading cause of serious infections particularly nosocomial infections mainly effecting the inpatients. The predominant infections observed were wound infections and urinary tract infections. The most common age group affected was between 21 to 30 years and Pseudomonas aeruginosa infections were equally distributed between males and females. The present study has demonstrated that 33% of pseudomonas aeruginosa are MBL producers and developing resistance to commonly prescribed antimicrobial agents such as Azithromycin, Cefepime, Ciprofloxacin, Gentamicin and Ceftazidime. MBL producers were resistant to Imipenem and Meropenem. The emergence of multidrug resistant Pseudomonas aeruginosa due to the indiscriminate use of antibiotics is a challenging clinical problem which leads to the Volume XIV Issue VII Version I Year ( ) 2014 development of resistance to the routinely used antibiotics. There is a need to do surveillance to know the susceptibility pattern and to detect the MBL producers. MBL producers cause problems in treatment and in infection control. Revised guidelines on rational antibiotic usage are to be reinforced. Infection control measures must be intensified to minimize costs of patient care. [1]

1

2014
Year
Volume XIV Issue VII Version I
( )

Type of sample	Number of samples
Pus	52 (39.39%)
Urine	50 (37.87%)
Sputum	10 (7.57%)
Stool	04 (3.03%)
BAL	06 (4.54%)
ASF	02 (1.54%)
ET	04 (3.03%)
PLF	04 (3.03%)
Total	132 (100%)
Pleural fluid	

Out of 132 isolates Pseudomonas aeruginosa was isolated from 120 (90.50%) inpatients and 12 (9.50%) out patients.

Age wise distribution of Pseudomonas aeruginosa was as follows. 32 (24.24%) isolates were in the age group of 21 to 30, 11 (16.66%) isolation were in the age group of 31 to 40, 20 (15.15%) isolates were from the age group of 41 to 50, 14 (10.62%) isolates were in the both in 0 to 10 and 51 to 60 years, 10 (7.57%) isolates were in the age group of 61 to 70 and the rest of the 6 (4.54%) isolates were seen in above 70 years of age. This shows that Pseudomonas aeruginosa infections are not confined to particular age group but distributed in all age groups with slight variation.

Out of 132 isolates MBL enzyme production was seen in 44 (33.34%) cases and in 88 (66.66%) cases there was no MBL production. The ATCC 27853 Pseudomonas aeruginosa did not show any zone size enhancement by Double Disk Synergy Test (DDST).

(Table 2)

Table 2 : MBL production in P.aeruginosa

MBL	Number of cases
MBL positive	44 (33.34%)
MBL Negative	88(66.66%)
Total	132 (100%)

[Note: BAL: Broncho alveolar lavage, ASF: Ascitic fluid, ET: Endotracheal tube, PLF:]

Figure 1: Table 1 :

3

Antibiotics (µg)	MBL Positive n=44(33.34%)	MBL Negative n=88 (66.6%)
Gentamicin (10)	0	52(59%)
Ciprofloxacin (5)	5 (11.3%)	29 (65%)
Cefepime (30)	3 (6.8%)	40 (45.4%)
Ceftazidime (30)	5 (11.3%)	52 (59%)
Ceftriaxone (30)	5 (11.3%)	25 (28%)
Azithromycin (50)	3 (6.8%)	10 (11.3%)
Piperacillin/Tazobactam (100/10)	20 (45.4%)	44 (95.4%)
Imipenem (10)	0	20(22%)
Meropenem (10)	0	21(23%)
Colistin (10)	100 (100%)	100 (100%)
Aztreonam (10)	3(6.8%)	23 (25%)
P<0.05		

[Note: Graph : showing antibiotic sensitivity pattern for both MBL and non MBL producers]

Figure 2: Table 3 :

4

Clinical specimen	P.aeruginosa (n-132)	MBL Producers(n=44)
Pus	52	18 (40.90%)
Urine	50	16(36.36%)
Sputum	10	04(9.09%)
ASF	02	02 (4.45%)
PLF	04	02 (4.45%)
ET	04	02 (4.45%)
Stool	04	00
BAL	06	00
Total	132	44(100%)

Figure 3: Table 4 :

[Antimicrob Agents Chemother] , *Antimicrob Agents Chemother* 39 p. .

[Indian J Med Microbiol] , *Indian J Med Microbiol* 23 p. .

[Karachi] , Pakistan ' Karachi . *BJMP* 2 (4) p. .

[Erdem and Pseudomonas (ed.) ()] , B Erdem , Pseudomonas . Basic Clinical. Microbiology. Ed.Ustacelebi S Ankara (ed.) 1999. Gunes Publication. p. .

[Sarkar et al. ()] 'A clinical microbiological study on the importance of Pseudomonas in nosocomially infected ICU patients, with special reference to metallo ?lactamase production''. B Sarkar , D Biswas , Prasad R Sharma , JP . *Indian J PathoMicrobiol* 2006. 49 p. .

[Bush et al. ()] *A functional classification scheme for beta lactamase and its correlation with molecular structure*, K Bush , G A Jacoby , A Medeiros . 1995.

[Navneeth et al. ()] 'A preliminary study on metallobetalactamases producing of P. aeruginosa in hospitalized patients'. Indian'. B Navneeth , D Shridaran , D Sahay , Mrs Belwadi . *J Med Res* 2002. 116 p. .

[Prince ()] 'Antibiotic resistance of Pseudomonas species'. A Prince . *J Pediatr* 1986. 108 p. .

[Javiya et al. ()] 'Antibiotic susceptibility patterns of Pseudomonas aeruginosa at a tertiary care hospital in Gujarat, India''. V A Javiya , S B Ghatak , J A Patel . *Indian J pharmacol* 2008. 40 p. .

[Richet et al. ()] 'Building communication networks: international network for the study and prevention of emerging antimicrobial resistance'. H M Richet , J Mohammed , L C Mcdonald , W R Jarvis . *Emerg Infect Dis* 2001. 7 p. .

[Nadeem et al. ()] *Comparison of the invitro susceptibility of clinical isolates of Pseudomonas aeruginosa in a local hospital setting in*, S G Nadeem , S A Qasmi , F Afaque , M Saleem , S T Hakim . 2009.

[Jesudason et al. ()] 'Comparison of two methods to detect carbapenemase and Metallo-?-lactamase production in clinical isolates''. M V Jesudason , A J Kandathil , V Balaji . *Indian J Med Res* 2005. 121 p. .

[Rakesh et al. ()] 'Detection and antimicrobial susceptibility pattern of Pseudomonas aeruginosa isolates in various clinical samples with special reference to Metallo beta lactamase from a tertiary care hospital in Jaipur'. K Rakesh , S Preeti , R Suman , S S Dahiya , H Kirti , P S Nirwan . *National journal of medical research* 2014. 4 p. .

[Bashir et al. (2011)] 'Detection of Metallo-beta-lactamase (MBL) producing Pseudomonas aeruginosa at a tertiary care hospital in Kashmir'. D Bashir , M A Thokar , B A Fomda , G Bashir , D Zahoor , Ahmad S Abubaker , ST . *African journal of Microbiology Research* 2011. 18 January. 5 (2) p. .

[Hemalatha et al. ()] 'Detection of metallobetalactamases producing P.aeruginosa in hospitalized patients''. V Hemalatha , U Sekar , V Kamat . *Nigerian Journal of. Pharmaceutical Sciences* 2005. 122 p. . (Indian J Med Res)

[Bush ()] 'Emerging epidemic of Metallo-?-lactamasemediated resistance'. K Bush . *Clin Infect Dis* 1998. 27 p. . (Metallo-?-lactamases: A class apart)

[Gupta et al. ()] 'Emerging resistance to Carbapenems in a tertiary care hospital in north India''. E Gupta , S Mohanty , S Sood , B Dhawan , B K Das , A Kapil . *Indian J Med Res* 2006. 124 p. 958.

[Gladstone et al. ()] *Incidence of carbapenem resistant nonfermenting gram negative bacilli from patients with respiratory infections in the intensive care unit*, P Gladstone , P Rajendran , K N Brahmadathan . 2005.

[Seema et al. ()] *Incidence of Metallo beta lactamases producing*, B Seema , Atindra Krishna , G Rekha , B . 2012.

[Bennett ()] 'Integrons and gene cassettes: A genetic construction Kit for bacteria'. P M Bennett . *Antimicrob Agents Chemother* 1999. 43 p. .

[David Greenwood Richard et al. ()] *Medical Microbiology' 16/c*, C B David Greenwood Richard , F Slack John , Peuther . Livingstone. 28. 2008. Greenwood, etal. p. 282.

[Attal et al. ()] 'Metallobetalactamase producing Pseudomonas Aeruginosa: An Emerging threat To Clinicians'. R O Attal , S Basak , S K Mallick , S Bose . *Journal of clinical and Diagnostic Research* 2010. (4) p. .

[Mendiratta et al. ()] 'Metallobetalactamases producing of P.aeruginosa in hospital from rural area''. D K Mendiratta , V Deotale , P Narang . *Indian J Med Res* 2005. 121 p. .

[Li et al. ()] *Most strains of Pseudomonas aeruginosa are significantly more resistant, even in antimicrobial agents, including beta-lactams, tetracycline, chloramphenicol, and Norfloxacin'. Antimicrob.Agents chemother*, X Z Li , D M Livermore , H Nikaido . 1994. 38 p. .

[Livermore ()] 'Role of beta-lactamase and impermeability in the resistance of Pseudomonas aeruginosa'. D M Livermore . *J.Antimicrob.chemother* 1989. 42 p. .

[Agrawal et al. ()] 'Study of metallobetalactamases production in clinical isolates of P. aeruginosa''. G Agrawal , R B Lodhi , U P Kamalakar , R K Khadse , S V Jalgaokar . *Indian J Med Microbiol* 2008. 26 (4) p. .